Myriad Genetics stock opened at $24.44 on Tuesday. The stock has a market cap of $1.96 billion, a PE ratio of -64.32 and a beta of 1.53. The stock has a 50-day moving average price of $25.14 and a 200 day moving average price of $27.24. Myriad Genetics has a 52 week low of $22.35 and a 52 week high of $36.95.
Myriad Genetics (NASDAQ:MYGN – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $160.80 million during the quarter, compared to analysts’ expectations of $162.21 million. Myriad Genetics had a negative return on equity of 2.93% and a negative net margin of 3.94%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.19) EPS. Equities research analysts predict that Myriad Genetics will post -0.31 EPS for the current fiscal year.
Large investors have recently modified their holdings of the business. Rockefeller Capital Management L.P. boosted its stake in Myriad Genetics by 209.5% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 1,238 shares of the company’s stock worth $39,000 after buying an additional 838 shares during the last quarter. Spire Wealth Management acquired a new position in shares of Myriad Genetics in the 4th quarter valued at about $48,000. Banque Cantonale Vaudoise acquired a new position in shares of Myriad Genetics in the 3rd quarter valued at about $65,000. Itau Unibanco Holding S.A. acquired a new position in shares of Myriad Genetics in the 4th quarter valued at about $81,000. Finally, CWM LLC acquired a new position in shares of Myriad Genetics in the 4th quarter valued at about $99,000. 98.54% of the stock is currently owned by hedge funds and other institutional investors.
About Myriad Genetics (Get Rating)
Myriad Genetics, Inc, a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
- Get a free copy of the StockNews.com research report on Myriad Genetics (MYGN)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.